Liver Disease clinical trials at UC Irvine

2 research studies open to eligible people

Showing trials for

  • Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

    open to eligible people ages 18 years and up

    The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

    Orange 5379513, California 5332921 and other locations

  • Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

    open to eligible people ages 18-99

    This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

    Orange 5379513, California 5332921 and other locations

Last updated: